Cargando…

Spotlight on Sotorasib (AMG 510) for KRAS(G12C) Positive Non-Small Cell Lung Cancer

Mutations in codon 12 of KRAS have been identified in 13% of non-small cell lung cancer patients. Developing targeted therapies against KRAS(G12C) mutation has proven to be challenging due to the abundance of GTP in the cytoplasm, rapid hydrolysis of GTP, and difficulty designing small molecules to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shannon S, Nagasaka, Misako
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504654/ https://www.ncbi.nlm.nih.gov/pubmed/34675734 http://dx.doi.org/10.2147/LCTT.S334623

Ejemplares similares

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
por: Brazel, Danielle, et al.
Publicado: (2023)

CodeBreak 200: Sotorasib Has Not Broken the KRAS(G12C) Enigma Code
por: Zhang, Shannon S, et al.
Publicado: (2023)

Understanding the influence of AMG 510 on the structure of KRAS(G12C) empowered by molecular dynamics simulation
por: Li, Yu, et al.
Publicado: (2022)

KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations
por: Pantsar, Tatu
Publicado: (2020)

Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRAS(G12C)
por: Zhuang, Haiming, et al.
Publicado: (2022)

Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research
por: Wu, Lei-Lei, et al.
Publicado: (2023)

Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report
por: Iska, Sindu, et al.
Publicado: (2023)

Sotorasib Shows Intracranial Activity in Patients with KRAS G12C-Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases
por: Koster, Kira-Lee, et al.
Publicado: (2022)

DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS(G12C)-mutant cancer
por: Chiou, Li-Wen, et al.
Publicado: (2023)

Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Parums, Dinah V.
Publicado: (2022)

Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With KRAS(G12C)-Mutant Non–Small-Cell Lung Cancer
por: Lamberti, Giuseppe, et al.
Publicado: (2023)

Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations
por: Lanman, Brian A., et al.
Publicado: (2022)

De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report
por: Ito, Takanori, et al.
Publicado: (2023)

Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
por: Begum, Parvin, et al.
Publicado: (2021)

Remarkable Intracranial Response to Sotorasib in a Patient With KRAS(G12C)-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report
por: Yeh, Justin, et al.
Publicado: (2022)

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
por: Brazel, Danielle, et al.
Publicado: (2022)

BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers
por: Khan, Sajid, et al.
Publicado: (2022)

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
por: Inno, Alessandro, et al.
Publicado: (2023)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel, Danielle, et al.
Publicado: (2021)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

Rapid Response to Sotorasib of a Patient With KRAS G12C-Mutated Lung Cancer With Cancer-Associated Disseminated Intravascular Coagulation: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Tolerability of sotorasib for KRAS positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report
por: Okada, Kohei, et al.
Publicado: (2023)

Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG-510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL-XL
por: Kitazawa, Masato, et al.
Publicado: (2021)

Evaluation of AMG510 Therapy on KRAS-Mutant Non–Small Cell Lung Cancer and Colorectal Cancer Cell Using a 3D Invasive Tumor Spheroid System under Normoxia and Hypoxia
por: Huang, Meng, et al.
Publicado: (2022)

Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells
por: Padmanabhan, Jaya, et al.
Publicado: (2021)

Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
por: Wang, Yini, et al.
Publicado: (2023)

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
por: Dy, Grace K., et al.
Publicado: (2023)

Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations
por: Ahn, Jeffrey, et al.
Publicado: (2023)

Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

Anticancer Efficacy of KRAS(G12C) Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS(G12C)-Mutant Pancreatic and Lung Cancers
por: Khan, Husain Yar, et al.
Publicado: (2023)

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
por: Azar, Ibrahim, et al.
Publicado: (2021)

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
por: Khan, Husain Yar, et al.
Publicado: (2022)

Correction to: Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer
por: Blaquier, Juan Bautista, et al.
Publicado: (2021)

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib
por: Nolan, Aoife, et al.
Publicado: (2023)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_96kblm34dfbshfuha0tdqdvhcd